

# QTL Analysis Identifies a Modifier Locus of Aganglionosis in the Rat Model of Hirschsprung Disease Carrying *Ednrb*<sup>sl</sup> Mutations

Ruihua Dang, Daisuke Torigoe, Nobuya Sasaki, Takashi Agui\*

Laboratory of Laboratory Animal Science and Medicine, Department of Disease Control, Graduate School of Veterinary Medicine, Hokkaido University, Hokkaido, Japan

## Abstract

Hirschsprung disease (HSCR) exhibits complex genetics with incomplete penetrance and variable severity thought to result as a consequence of multiple gene interactions that modulate the ability of enteric neural crest cells to populate the developing gut. As reported previously, when the same null mutation of the *Ednrb* gene, *Ednrb*<sup>sl</sup>, was introgressed into the F344 strain, almost 60% of F344-*Ednrb*<sup>sl/sl</sup> pups did not show any symptoms of aganglionosis, appearing healthy and normally fertile. These findings strongly suggested that the severity of HSCR was affected by strain-specific genetic factor (s). In this study, the genetic basis of such large strain differences in the severity of aganglionosis in the rat model was studied by whole-genome scanning for quantitative trait loci (QTLs) using an intercross of (AGH-*Ednrb*<sup>sl</sup> × F344-*Ednrb*<sup>sl</sup>) F<sub>1</sub> with the varying severity of aganglionosis. Genome linkage analysis identified one significant QTL on chromosome 2 for the severity of aganglionosis. Our QTL analyses using rat models of HSCR revealed that multiple genetic factors regulated the severity of aganglionosis. Moreover, a known HSCR susceptibility gene, *Gdnf*, was found in QTL that suggested a novel non-coding sequence mutation in GDNF that modifies the penetrance and severity of the aganglionosis phenotype in *EDNRB*-deficient rats. A further identification and analysis of responsible genes located on the identified QTL could lead to the richer understanding of the genetic basis of HSCR development.

**Citation:** Dang R, Torigoe D, Sasaki N, Agui T (2011) QTL Analysis Identifies a Modifier Locus of Aganglionosis in the Rat Model of Hirschsprung Disease Carrying *Ednrb*<sup>sl</sup> Mutations. PLoS ONE 6(11): e27902. doi:10.1371/journal.pone.0027902

**Editor:** Shree Ram Singh, National Cancer Institute, United States of America

**Received:** August 31, 2011; **Accepted:** October 27, 2011; **Published:** November 22, 2011

**Copyright:** © 2011 Dang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** The authors have no support or funding to report.

**Competing Interests:** The authors have declared that no competing interests exist.

\* E-mail: agui@vetmed.hokudai.ac.jp

## Introduction

Hirschsprung disease (HSCR) is a congenital malformation characterized by the absence of intramural ganglion cells along variable lengths of the distal gut. Due to the lack of ganglia, the stool cannot be passed through the colon, and the bowel wall is dilated [1–4]. The disorder is classified into short-segment (S-HSCR, 80%), long-segment (L-HSCR, 15%), or total colonic aganglionosis (TCA, 5%) [5]. HSCR is observed in about 1/5000 live birth and is more frequent in males than in females (4:1), a difference most prominent in S-HSCR [6]. Several genes have been implicated in the development of HSCR, including the *RET* proto-oncogene [7–9], endothelin receptor B gene (*EDNRB*) [10–17], endothelin-3 gene (*EDN3*) [18,19], glial-cell-line-derived neurotrophic factor (*GDNF*) [20–22], *SOX10* [23,24], *NRTN* [25], *ECE1* [26], *ZFH1B* [27], *PHOX2B* [28], *KIAA1279* [29], *TCF4* [26]. However, mutations in these genes explain only a minority of cases and the vast majority (80%) of HSCR heritability remains unknown [30]. HSCR displays a highly variation in penetrance and phenotypes by gender, familial incidence, segment length of aganglionosis and associated phenotypes. The variable penetrance and expressivity of this disease are attributed to the complex genetic interactions between the known susceptibility loci and undiscovered susceptibility or modifier loci in the genetic background that modulates the ability of enteric neural crest cells to populate the developing gut [31].

Many researchers have used inbred models to search the unknown susceptibility or modifier genes of aganglionosis [31,32]. Moreover, mouse models, in which genetic background and input alleles can be controlled in genome-wide and candidate gene approaches, are a strong tool to identify the novel genetic factors or modifiers that influence the variable penetrance and inheritance patterns of complex diseases like HSCR. Spotting lethal (*sl*) is a spontaneous null mutation that has a 301 bp deletion in the rat *Ednrb* gene that results in the absence of a functional receptor protein [33]. In the previous study, we established an AGH-*Ednrb*<sup>sl</sup> [34] inbred strain carrying the *sl* mutation, further, introgressed this mutation into LEH and F344 strains to produce two congenic strains: LEH-*Ednrb*<sup>sl</sup> and F344-*Ednrb*<sup>sl</sup> [34]. In AGH-*Ednrb*<sup>sl/sl</sup> rats, only 20% of pups survived until weaning; whereas in F344-*Ednrb*<sup>sl/sl</sup> rats, 100% of pups survived to weaning. Interestingly, almost 60% of F344-*Ednrb*<sup>sl/sl</sup> pups did not show any symptoms of aganglionosis, appearing healthy and normally fertile and showing normal body weight gain. Thus, we concluded that variation in the penetrance and survival was attributable to distinct differences in the severity of aganglionosis, and resistant genes in the genetic background of F344 significantly modulated the severity of the aganglionosis phenotype.

This study focuses on the variation in aganglionosis between individual *Ednrb*<sup>sl</sup>-mutated rats and uses this variation to identify modifiers that are influencing the aganglionosis aspect of the phenotype. These studies have been facilitated by the ability to

control genetic background in inbred lines of *Ednrb<sup>sl/sl</sup>* rats that are not possible in patient studies.

**Results**

**Evaluation of aganglionosis as a quantitative trait in F<sub>2</sub> *Ednrb<sup>sl/sl</sup>* rats**

Homozygous *Ednrb<sup>sl/sl</sup>* rats showed aganglionosis phenotypes. In our previous study, we found that when the *sl* mutation was introgressed into the F344 strain, the phenotype of aganglionosis was strongly modified [34]. As shown in Fig. 1, AGH-*Ednrb<sup>sl/sl</sup>* rats at postnatal 14 day exhibited abnormal dilation of the intestines resulting from the absence of ganglion cells in a long segment beyond caecum. In contrast, in F344-*Ednrb<sup>sl/sl</sup>* pups at postnatal 14 day, an enlarged small intestinal phenotype (mega small intestine) was not found. We have confirmed that the variation in the expressivity of this disease between these two strains was caused from the extent of aganglionosis by whole-mount acetylcholinesterase (AChE) staining [34]. We used the same method to establish the range of phenotypes among the F<sub>2</sub> (AGH×F344) *Ednrb<sup>sl/sl</sup>* progenies. The F<sub>2</sub> animals (n = 410) were produced by heterozygotes mating between AGH and F344 strains and then 96 *Ednrb<sup>sl/sl</sup>* pups were selected to phenotype based on the difference in skin pigmentation pattern between homologous mutants and other


genotype rats or genotyping for the *Ednrb<sup>sl</sup>* mutation (for albino pups). The number of *Ednrb<sup>sl/sl</sup>* pups was consistent with the anticipated 25% transmission ratio. Microscopic examination of *Ednrb<sup>sl/sl</sup>* intestines stained by AChE was used to appraise the length of aganglionosis gut, then the extent of aganglionosis was calculated as a ratio of length of the aganglionosis intestine to the length of the entire large intestine used as a quantitative trait in individual animals. We also recorded the gross intestine weight and body weight of pups at postnatal 14 day, and to fully capture the difference between sick and healthy ones, the ratio of gross intestine weight (gross intestine weight/body weight) was calculated, which demonstrates the expressivity of megacolon directly. We found that there was a high correlation between the aganglionosis extent and the ratio of gross intestine weight in F<sub>2</sub> populations (Fig. 2). This showed that the ratio of aganglionosis extent is appropriate as a quantitative trait for the severity of aganglionosis. The specificity and sensitivity of the extent of aganglionosis as a quantitative trait were confirmed by following experiments using MapManager QTXb.

The range of the aganglionosis extent for each progeny is presented as black characters in Fig. 3A, which was fairly scattered for F<sub>2</sub> intercross progenies, while that of the AGH and F344 progenies tended to fall on one of the two extremes. The mean ratio of the F<sub>2</sub> progenies (0.95 in ratio of aganglionosis extent) composed of each homozygote of AGH and F344, and the heterozygotes were nearly the same as that of the F<sub>1</sub> progenies (1.08 in ratio of aganglionosis extent).


In Fig. 3B and 3C, individual traits of the male and female F<sub>2</sub> progenies are arranged by size of the ratio of aganglionosis extent. The trait-value graphs in both males and females showed similar gentle curves, which suggests that the mild aganglionosis extent in F344-*Ednrb<sup>sl/sl</sup>* rats are under the control of polygenic inheritance.

**QTL analysis identifies modifiers of aganglionosis severity in *Ednrb<sup>sl/sl</sup>* rats**


Final results of interval mapping were considered suggestive, significant, or highly significant linkages when the threshold likelihood ratio statistics (LRS) were 9.9, 20.2, and 30.4, respectively. As shown in Fig. 4, the highest linkage over the significant level (LRS>20.2) appeared on Chr 2. The maximum LRS score was 23.9 on Chr 2. Linkage details were shown in Fig. 5. The locus at the *D2Mit5* marker



**Figure 1. Comparison of the expressivity of aganglionosis.** 14-day-old AGH-*Ednrb<sup>sl/sl</sup>* rats (left) show severe symptoms of aganglionosis, but not in F344-*Ednrb<sup>sl/sl</sup>* rats (right). doi:10.1371/journal.pone.0027902.g001



**Figure 2. Correlation analysis between the severity of aganglionosis and the ratio of gross intestine weight.** Correlation analysis between the severity of aganglionosis (aganglionosis length/large intestine length) and the ratio of gross intestine weight (gross intestine weight/body weight) shows a high correlation between the two traits. doi:10.1371/journal.pone.0027902.g002




**Figure 3. The range of the aganglionosis extent.** (A) The range of the aganglionosis extent in 14-day old pups from AGH-*Ednrb*<sup>sl/sl</sup>, F344-*Ednrb*<sup>sl/sl</sup>, F<sub>1</sub>, and F<sub>2</sub>. Mean values are indicated by horizontal lines. Distribution of the severity of aganglionosis in male (B) and female (C) F<sub>2</sub> progenies. doi:10.1371/journal.pone.0027902.g003

position, showing the highest linkage to the severity of aganglionosis (LRS = 23.9), was designated '*Lrag1* (*Locus of resistance to aganglionosis 1*)'. The epistatic interaction between markers also was searched by MapManager QTXb, but no significant interaction was found.


**Allele effects of *Ednrb*<sup>sl/sl</sup> modifier loci**

Modifier loci either can increase susceptibility and severity of phenotype or can act protectively to confer resistance to disease in

the face of a predisposing mutation [35]. To assess the effects of individual *Ednrb*<sup>sl/sl</sup> modifiers on the severity of aganglionosis, we evaluated complete genotype information in the total F<sub>2</sub> distribution. F344 alleles at modifier locus on chromosome 2 decreased the extent of gut length affected by aganglionosis (Fig. 6). The allele effect observed was approximately dominant, with heterozygotes exhibiting phenotypes equal to the phenotypes of the homozygous animals of F344 alleles.




**Figure 4. Result of interval mapping scans by MapManager QTXb in F<sub>2</sub> rats.** Analyses of linkage of aganglionosis severity in F<sub>2</sub> populations to chromosomal loci were performed using the MapManager QTXb20 software. Recombination frequencies (%) were converted into genetic distance (centiMorgan; cM) using the Kosambi map function, in which linkage data are provided as likelihood ratio statistic (LRS) scores. Genome-wide significance thresholds were calculated in terms of LRS by carrying out permutation tests for 500 permutations. The thresholds for suggestive (Su), significant (Si) linkages are indicated in dotted and thin lines, respectively. LRS, likelihood ratio statistic. doi:10.1371/journal.pone.0027902.g004



**Figure 5. Details of suggestive and significant linkages in QTL analysis of the severity of aganglionosis.** The QTL on chromosome 2 (*Lrag1*) showed a significant linkage to aganglionosis severity, respectively. The dotted and thin lines represent suggestive (Su) and significant (Si) thresholds, respectively. The microsatellite markers used for determining genotypes of F<sub>2</sub> rats are presented along the X-axis. LRS, likelihood ratio statistic. doi:10.1371/journal.pone.0027902.g005

**Identification of candidate genes in chromosome 2**

By bioinformatics methods combining genome annotation with literature searches, some biologically relevant genes within modifier intervals have been identified successfully [36]. We used the positions of the closest markers flanking the peak on Chr 2 to define the boundaries of this interval on the rat genome assembly and searched for genes that might be involved in development of enteric neural system based on their expression profiles in the literature and public databases. More than 30 genes within this interval were identified by NCBI. This listing of candidates was narrowed to include only those genes associated with cell migration, the development of enteric nervous system based on information in the PosMed and in the Gene Expression Database



**Figure 6. Effect of alleles at *Ednrb<sup>sl/sl</sup>* modifier loci on the severity of aganglionosis.** Genotypes from the total F<sub>2</sub> population obtained from the marker closest to the modifier were used to assess the effects of individual loci on the severity of phenotype. The mean of aganglionosis severity (aganglionosis length/large intestine length) is plotted for each genotype class to show the relation of the number of AGH or F344 alleles and the extent of aganglionosis for this locus. Markers used to generate genotype information are listed beneath the plot. Genotype groups are defined as AGH/AGH (AA), AGH/F344 (AF) and F344/F344 (FF). doi:10.1371/journal.pone.0027902.g006

(Table 1). Within these genes, two highly relevant candidates were identified based on their documented expression in the developing gut. These included *Gdnf* and *Rai14* genes. *Rai14* is expressed early in the neural tube of 9.5-day mouse embryo and maintained in intestines. *Gdnf* encodes a highly conserved neurotrophic factor, which promotes the survival of many types of neurons. *Gdnf*-null mice showed a complete absence of the enteric nervous system, ureters, and kidneys [37]. *GDNF* is established to be important in the development of the enteric nervous system and Hirschsprung disease. So it is a logical and possible candidate modifier. We sequenced the coding region of *Gdnf*, but failed to find a difference between the two rat strains. Subsequently, we also compared the expression level of *Gdnf* mRNA of the whole intestine tissue from wildtype and heterozygous AGH and F344 rats in embryonic day 15.5 by RT-PCR. However, no difference was found (data not shown).

**Discussion**

The enteric nervous system (ENS) mostly derives from migratory vagal neural crest cells. A minority of the foregut ENS also arise from migratory anterior trunk neural crest cells of the posterior vagal region [4]. Neural crest cells enter the foregut at embryonic day 9–9.5 in mice, in this time they are termed enteric neural crest-derived cells (ENCCs) [4]. These progenitor cells of enteric nervous system migrate in a rostral to caudal direction to sequentially colonize the foregut, midgut, and last the hindgut, which is complete by embryonic day 15 [2,4]. Neural crest cells from sacral levels of the neural tube also colonize the gut, where they contribute to only a small fraction of enteric neurons and glia in the distal midgut and hindgut [2,4]. ENCCs proliferate actively to expand the relatively small pool of progenitors and then differentiate into phenotypically distinct neuronal subtypes and glia. The multi-step, complex nature of ENS ontogeny suggests that it is vulnerable to alterations in the function or expression of many genes as well as changes in the environment. When this progress is disturbed, a congenital gut motility disorder, HSCR occurs, which is characterized by an absence of enteric neurons in terminal regions of the gut. HSCR is a complex disease manifesting with low, sex-dependent penetrance and variability in the length of the aganglionic segment [32].

In human with HSCR, the genetic interaction between mutations in *RET* and *EDNRB* was found in an association study conducted on Mennonite family with the W276C mutations in the *EDNRB* [38]. The combination of these two genotypes increased

**Table 1. List of candidate genes for *Lrag1*.**

<i>Lrag1</i> candidates on Chr 2		
Gene symbol	Gene description	Mbp
<i>D2Arb7</i>	Flanking marker	57.2
<i>Gdnf</i>	Glial cell line-derived neurotrophic factor	57.4
<i>Rai14</i>	Retinoic acid induced 14	59.9
<i>Zfr</i>	Zinc finger RNA-binding protein	61.6
<i>Mttr12</i>	Myotubularin-related protein 12	61.6
<i>Mttr1</i>	Myotubularin related protein 1	61.7
<i>Golph3</i>	Golgi phosphoprotein 3	61.8
<i>Pdzd2</i>	PDZ domain containing 2	61.8
<i>D2Mit5</i>	Flanking marker	66.7

doi:10.1371/journal.pone.0027902.t001

the penetrance of the W276C mutation and therefore the risk of disease. Genetic interaction between *RET* and *EDNRB* pathways has also been demonstrated in mice [38–40]. In mice, heterozygosity for two known mutant HSCR genes, *RET*<sup>+/-</sup> and *Ednrb*<sup>sl</sup>, or *RET*<sup>+/-</sup> and *Ednrb*<sup>s</sup> genes, had no intestinal aganglionosis, whereas *RET*<sup>+/-</sup> mice with the homozygous *Ednrb*<sup>s</sup> or heterozygous *Ednrb*<sup>s</sup>/*Ednrb*<sup>sl</sup> mutations showed megacolon [38,40]. Thus, the synergistic effects of multiple mutations in HSCR-associated genes can influence disease penetrance and expressivity. The mechanisms underlying these interaction may help to explain the complexity of the HSCR phenotype and resolve puzzling genetic observations, such as variations in penetrance and severity of aganglionosis between family members carrying equivalent mutations in HSCR genes [41]. However, many susceptibility genes or modifier genes or interaction between them remain unknown. Animal models have greatly helped us to understand HSCR genetics and embryologic events that construct the ENS. Several susceptibility genes of HSCR are initially identified in mice that are later found to be altered in human HSCR patients [42,43].

In this study, we used quantitative trait locus (QTL) mapping to detect the genetic loci that contribute to differences in phenotypic variation of aganglionosis extent between F344 and AGH strains with the same null mutations. Using this comprehensive approach, we have successfully identified a modifier locus of *Ednrb*<sup>sl/sl</sup> on rat chromosomes 2. This locus contains a known aganglionosis susceptibility gene, *GDNF*. The *GDNF* ligand activates the *RET* receptor through the assembly of a multiprotein complex, including the *GDNF* family receptor *alpha1* (*GFRalpha1*) molecule, which have important functions in the development and maintenance of sensory, enteric, sympathetic and parasympathetic neurons and a variety of non-neural tissues [44]. The genetic interaction between mutations in *RET* and *EDNRB* has been well described in human patients and confirmed in mice [38–40]. So it is possible that there was an interaction between *Gdnf* ligand and *Ednrb*. Though we failed to find the sequence difference of coding region in *Gdnf* gene between both rat strains, we cannot completely exclude the possibility that *Gdnf* is a responsible gene because the non-coding regulatory region of *Gdnf* remains unknown which could affect the *Gdnf* expression in a specific timing that is important for the ENS development. Such case has been found in human with HSCR that a non-coding *RET* variant within a conserved enhancer-like sequence in intron 1 is significantly associated with HSCR susceptibility [45]. We only investigated the expression level of *Gdnf* in embryonic day 15.5. It remains unknown whether there is difference in the expression level at other developmental stage of ENS. The spacial and temporal control of gene expression in the complex process of ENCCs colonization of the gut is very important. *Ednrb* is genetically required in the mouse for ENS development in vivo from embryo day 10 to embryo day 12.5 [46]. The interaction of *RET* and *EDNRB* signaling pathways only influenced the ENS, no impact on melanocyte, retinal choroid, and kidney development, which showed a tissue-specific interaction [40]. All these lines of evidence suggested a possibility that a non-coding variant of *Gdnf* interacting with *Ednrb* mutation in AGH strain resulted in the serious aganglionosis.

Using congenic techniques, we are currently attempting to generate rat strains that harbor QTLs from one selection line on the opposite line to investigate whether each allele has a different effect on the phenotype. At the same time, several approaches are currently being employed to identify candidate genes located on *Lrag1*. Some of these approaches include comparisons of gene expression levels of F344 and AGH rats in intestine tissues using microarray and next-generation RNA sequencing technologies. This analytical combination that includes QTL mapping and gene

expression profiles has proven useful in the selection of candidate genes.

A lack of existing comprehensive information on the susceptibility genes and interaction between susceptibility loci or modifier loci contributing to HSCR disease in the genetic background makes it difficult to understand the genetic base for many cases of HSCR. However, our study localized chromosomal sites where the allelic differences in genes presented in F344 and AGH rats and strongly affected the occurrence and severity of HSCR using QTL analysis. This study provided the new evidence that Hirschsprung disease is the consequence of multiple gene interactions that modulate the ability of enteric neural crest cells to populate the developing gut.

## Materials and Methods

### Animals

Heterozygous AGH/Hkv-*Ednrb*<sup>sl</sup> (AGH) [34] and F344-*Ednrb*<sup>sl</sup> (F344) [34] rats were bred to generate F<sub>2</sub> animals (n = 410), in which 96 *Ednrb*<sup>sl/sl</sup> pups were selected to phenotype based on the difference in skin pigmentation pattern. Namely, heterozygous AGH-*Ednrb*<sup>sl</sup> rats had pigmented heads, backs, and tails. In contrast, homozygous mutant rats had almost no pigmentation on their heads previously described [34]. On the other hand, since F344 is an *albino* (tyrosinase mutant) strain, *albino* F<sub>2</sub> rats were genotyped to distinguish homozygote from heterozygote and wildtype by PCR. Animals were genotyped for *Ednrb*<sup>sl</sup> mutation using primers (F-CCTCCTGGACTAGAGGTTCC and R-ACGACTTAGAAAGCTACACT) that flank the site of the 301-base deletion. PCR products were electrophoresed in 2% agarose gels to distinguish the wild (511 bp) and mutant (210 bp) alleles. To determine the aganglionosis extent by strain, AGH (n = 33), F344 (n = 35), F<sub>1</sub> (n = 32) were raised. Animals were maintained in specific pathogen-free conditions with feeding and drinking allowed *ad libitum*. All research and experimental protocols were conducted according to the Regulation for the Care and Use of Laboratory Animals of Hokkaido University and were approved by the Animal Care and Use Committee of Hokkaido University (Approval ID: No. 110226).

### Microsatellite genotyping

The genome-wide scan was performed using 96 intercross progenies. Genomic DNA was extracted from tail clips of these intercross progenies using a standard protocol and was subjected to a genome-wide scan at 10–30 Mbp resolution using 94 polymorphic microsatellite markers (Table 2). PCR primers of the markers were identified in the Rat Genomic Database of Ensembl (<http://uswest.ensembl.org>). Amplified samples were electrophoresed in 10% acrylamide gels, stained with ethidium bromide, and photographed under an ultraviolet lamp.

### Whole-mount staining

The guts from pups at postnatal day 14 were dissected as a single piece from the proximal esophagus to the distal colon. Mesenteric attachments and the pancreas were removed, and the guts were then processed for acetylcholinesterase (AChE) whole-mount staining using routine protocols to visualize enteric ganglia [31]. The extent of the gut regions affected by aganglionosis was determined by microscopic examination. The entire length of the gut and the large intestine length, as well as any aganglionic regions, were measured. The length of the aganglionic segment was divided by the whole large intestine length to yield an aganglionosis ratio.

**Table 2.** Microsatellite markers used for genotyping  $AFF_2$  intercrossed progenies.

Microsatellite Markers	Position (Mbp)	Microsatellite Markers	Position (Mbp)	Microsatellite Markers	Position (Mbp)	Microsatellite Markers	Position (Mbp)	Microsatellite Markers	Position (Mbp)
D1Rat392	19	D3Rat276	18	D6Rat165	93	D11rat43	85	D17Rat11	30
D1Got45	36	D3Rat80	32	D6Rat11	115	D12Rat58	4	D17Rat12	33
D1Mgh6	87	D3Rat93	75	D14Mgh4	138	D12Got26	13	D17Mit4	71
D1Rat269	126	D3Rat287	98	D7Rat31	28	D12Rat76	29	D17Rat58	81
D1Rat163	163	D3Mit4	131	D7Rat21	96	D13Rat59	31	D18Rat132	25
D1Rat159	198	D3Rat78	146	D7Rat14	101	D13Rat85	72	D18Got63	67
D1Rat235	248	D3Rat2	164	D7Mit16	120	D13Mit4	90	D18Rat86	68
D2Rat1	9	D3Rat1	170	D8Mit5	32	D14Got35	29	D18Rat6	77
D2Rat191	21	D4Rat222	18	D8Rat33	73	D14Rat12	41	D19RAT15	15
D2Rat253	25	D4Mgh2	36	D8Mgh4	86	D14Rat38	99	D19Mit9	27
D2Mgh2	39	D4Rat122	64	D8Rat18	97	D15Rat5	22	D19Got53	49
D2Mgh14	42	D4Rat183	125	D9Got27	14	D15Rat6	32	D20Mgh5	11
D2Arb7	57	D4Rat141	151	D9Mit3	55	D15Rat11	51	D20Got38	39
D2Mit5	66	D4Rat64	156	D9Rat15	62	D15Mgh5	102	D20Got47	50
D2Rat21	75	D4Rat67	161	D9Rat99	87	D16Rat78	19		
D2Rat123	112	D5Rat196	103	D10Rat217	17	D16Rat3	45		
D2Mit8	148	D5Got47	131	D10Rat24	79	D16Got63	69		
D2Mit12	174	D5Got93	158	D10Rat7	105	D16Rat55	76		
D2Rat52	200	D5Rat44	159	D11Mit4	22	D16Got90	79		
D3Rat57	4	D6Rat30	48	D11Rat5	56	17Rat2	9		

$AFF_2$ : (AGH-Ednrb<sup>sl</sup> × F344-Ednrb<sup>sl</sup>) F<sub>2</sub>.  
doi:10.1371/journal.pone.0027902.t002

## Linkage analysis

To identify the aganglionosis modifier loci, genotyping data and the ratio of aganglionosis extent were analyzed by MapManager QTXb [47], whereby permutation tests were done in 1-cM steps for 500 permutations to determine the suggestive, significant, or very significant levels of statistics.

## References

- Skinner MA (1996) Hirschsprung's disease. *Curr Probl Surg* 33: 389–460.
- Amiel J, Sproat-Emison E, Garcia-Barcelo M, Lantieri F, Burzynski G, et al. (2008) Hirschsprung disease, associated syndromes and genetics: a review. *J Med Genet* 45: 1–14.
- Passarge E (2002) Dissecting Hirschsprung disease. *Nat Genet* 31: 11–12.
- Heanue TA, Pachnis V (2007) Enteric nervous system development and Hirschsprung's disease: advances in genetic and stem cell studies. *Nat Rev Neurosci* 8: 466–479.
- Alves MMM, Osinga J, Verheij JBG, Metzger M, Eggen BJJ, et al. (2010) Mutations in SCG10 Are Not Involved in Hirschsprung Disease. *PLoS One* 5.
- Badner JA, Sieber WK, Garver KL, Chakravarti A (1990) A Genetic-Study of Hirschsprung Disease. *American Journal of Human Genetics* 46: 568–580.
- Angrist M, Kauffman E, Slaugenhaupt SA, Matise TC, Puffenberger EG, et al. (1993) A gene for Hirschsprung disease (megacolon) in the pericentromeric region of human chromosome 10. *Nat Genet* 4: 351–356.
- Luo Y, Ceccherini I, Pasini B, Matera I, Bicocchi MP, et al. (1993) Close linkage with the RET protooncogene and boundaries of deletion mutations in autosomal dominant Hirschsprung disease. *Hum Mol Genet* 2: 1803–1808.
- Lyonnet S, Bolino A, Pelet A, Abel L, Nihoul-Fekete C, et al. (1993) A gene for Hirschsprung disease maps to the proximal long arm of chromosome 10. *Nat Genet* 4: 346–350.
- Amiel J, Attie T, Jan D, Pelet A, Edery P, et al. (1996) Heterozygous endothelin receptor B (EDNRB) mutations in isolated Hirschsprung disease. *Human Molecular Genetics* 5: 355–357.
- Attie T, Till M, Pelet A, Amiel J, Edery P, et al. (1995) Mutation of the Endothelin-Receptor-B Gene in Waardenburg-Hirschsprung-Disease. *Human Molecular Genetics* 4: 2407–2409.
- Syrris P, Carter ND, Patton MA (1999) Novel nonsense mutation of the endothelin-B receptor gene in a family with Waardenburg-Hirschsprung disease. *American Journal of Medical Genetics* 87: 69–71.
- Boardman JP, Syrris P, Holder SE, Robertson NJ, Carter N, et al. (2001) A novel mutation in the endothelin B receptor gene in a patient with Shah-Waardenburg syndrome and Down syndrome. *Journal of Medical Genetics* 38: 646–647.
- Kusafuka T, Wang YP, Puri P (1996) Novel mutations of the endothelin-B receptor gene in isolated patients with Hirschsprung's disease. *Human Molecular Genetics* 5: 347–349.
- Puffenberger EG, Hosoda K, Washington SS, Nakao K, deWit D, et al. (1994) A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease. *Cell* 79: 1257–1266.
- Auricchio A, Casari G, Staiano A, Ballabio A (1996) Endothelin-B receptor mutations in patients with isolated Hirschsprung disease from a non-inbred population. *Hum Mol Genet* 5: 351–354.
- Tanaka H, Moroi K, Iwai J, Takahashi H, Ohnuma N, et al. (1998) Novel mutations of the endothelin B receptor gene in patients with Hirschsprung's disease and their characterization. *Journal of Biological Chemistry* 273: 11378–11383.
- Edery P, Attie T, Amiel J, Pelet A, Eng C, et al. (1996) Mutation of the endothelin-3 gene in the Waardenburg-Hirschsprung disease (Shah-Waardenburg syndrome). *Nature Genetics* 12: 442–444.
- Hofstra RMW, Osinga J, TanSindhunata G, Wu Y, Kamsteeg EJ, et al. (1996) A homozygous mutation in the endothelin-3 gene associated with a combined Waardenburg type 2 and Hirschsprung phenotype (Shah-Waardenburg syndrome). *Nature Genetics* 12: 445–447.

20. Angrist M, Bolk S, Halushka M, Lapchak PA, Chakravarti A (1996) Germline mutations in glial cell line-derived neurotrophic factor (GDNF) and RET in a hirschsprung disease patient. *Nature Genetics* 14: 341–344.
21. Ivanchuk SM, Myers SM, Eng C, Mulligan LM (1996) De novo mutation of GDNF, ligand for the RET/GDNFR-alpha receptor complex, in Hirschsprung disease. *Human Molecular Genetics* 5: 2023–2026.
22. Salomon R, Attie T, Pelet A, Bidaud C, Eng C, et al. (1996) Germline mutations of the RET ligand GDNF are not sufficient to cause Hirschsprung disease. *Nat Genet* 14: 345–347.
23. Pingault V, Bondurand N, Kuhlbrodt K, Goerich DE, Prehu MO, et al. (1998) SOX10 mutations in patients with Waardenburg-Hirschsprung disease. *Nat Genet* 18: 171–173.
24. Southard-Smith EM, Angrist M, Ellison JS, Agarwala R, Baxevanis AD, et al. (1999) The Sox10(Dom) mouse: modeling the genetic variation of Waardenburg-Shah (WS4) syndrome. *Genome Res* 9: 215–225.
25. Borrego S, Ruiz-Ferrer M, Torroglosa A, Luzon-Toro B, Fernandez RM, et al. (2011) Novel mutations at RET ligand genes preventing receptor activation are associated to Hirschsprung's disease. *Journal of Molecular Medicine-Jmm* 89: 471–480.
26. Jiang Q, Ho YY, Hao L, Berrios CN, Chakravarti A (2011) Copy Number Variants in Candidate Genes Are Genetic Modifiers of Hirschsprung Disease. *PLoS One* 6.
27. Sasongko TH, Sadewa AH, Gunadi, Lee MJ, Koterazawa K, et al. (2007) Nonsense mutations of the ZFX1B gene in two Japanese girls with Mowat-Wilson syndrome. *Kobe J Med Sci* 53: 157–162.
28. Fitze G, Konig IR, Paditz E, Serra A, Schlafke M, et al. (2008) Compound effect of PHOX2B and RET gene variants in congenital central hypoventilation syndrome combined with Hirschsprung disease. *Am J Med Genet A* 146A: 1486–1489.
29. Brooks AS, Bertoli-Avella AM, Burzynski GM, Breedveld GJ, Osinga J, et al. (2005) Homozygous nonsense mutations in KIAA1279 are associated with malformations of the central and enteric nervous systems. *Am J Hum Genet* 77: 120–126.
30. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, et al. (2009) Finding the missing heritability of complex diseases. *Nature* 461: 747–753.
31. Cantrell VA, Owens SE, Chandler RL, Airey DC, Bradley KM, et al. (2004) Interactions between Sox10 and EdnrB modulate penetrance and severity of aganglionosis in the SOX10(Dom) mouse model of Hirschsprung disease (vol 13, pg 2289, 2004). *Human Molecular Genetics* 13: 3241–3241.
32. Owens SE, Broman KW, Wiltshire T, Elmore JB, Bradley KM, et al. (2005) Genome-wide linkage identifies novel modifier loci of aganglionosis in the Sox10Dom model of Hirschsprung disease. *Hum Mol Genet* 14: 1549–1558.
33. Garipey CE, Cass DT, Yanagisawa M (1996) Null mutation of endothelin receptor type B gene in spotting lethal rats causes aganglionic megacolon and white coat color. *Proc Natl Acad Sci U S A* 93: 867–872.
34. Dang R, Torigoe D, Suzuki S, Kikkawa Y, Moritoh K, et al. (2011) Genetic background strongly modifies the severity of symptoms of hirschsprung disease, but not hearing loss in rats carrying ednrB mutations. *PLoS One* 6: e24086.
35. Nadeau JH (2003) Modifier genes and protective alleles in humans and mice. *Curr Opin Genet Dev* 13: 290–295.
36. Cozma D, Lukes L, Rouse J, Qiu TH, Liu ET, et al. (2002) A bioinformatics-based strategy identifies c-Myc and Cdc25A as candidates for the Apmt mammary tumor latency modifiers. *Genome Res* 12: 969–975.
37. Moore MW, Klein RD, Farinas I, Sauer H, Armanini M, et al. (1996) Renal and neuronal abnormalities in mice lacking GDNF. *Nature* 382: 76–79.
38. Carrasquillo MM, McCallion AS, Puffenberger EG, Kashuk CS, Nouri N, et al. (2002) Genome-wide association study and mouse model identify interaction between RET and EDNRB pathways in Hirschsprung disease. *Nature Genetics* 32: 237–244.
39. Barlow A, de Graaff E, Pachnis V (2003) Enteric nervous system progenitors are coordinately controlled by the G protein-coupled receptor EDNRB and the receptor tyrosine kinase RET. *Neuron* 40: 905–916.
40. McCallion AS, Stames E, Conlon RA, Chakravarti A (2003) Phenotype variation in two-locus mouse models of Hirschsprung disease: Tissue-specific interaction between Ret and EdnrB. *Proceedings of the National Academy of Sciences of the United States of America* 100: 1826–1831.
41. Cohen IT, Gadd MA (1982) Hirschsprung's disease in a kindred: a possible clue to the genetics of the disease. *J Pediatr Surg* 17: 632–634.
42. Yanagisawa H, Yanagisawa M, Kapur RP, Richardson JA, Williams SC, et al. (1998) Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene. *Development* 125: 825–836.
43. Southard-Smith EM, Kos L, Pavan WJ (1998) Sox10 mutation disrupts neural crest development in Dom Hirschsprung mouse model. *Nat Genet* 18: 60–64.
44. Airaksinen MS, Saarma M (2002) The GDNF family: signalling, biological functions and therapeutic value. *Nat Rev Neurosci* 3: 383–394.
45. Emison ES, McCallion AS, Kashuk CS, Bush RT, Grice E, et al. (2005) A common sex-dependent mutation in a RET enhancer underlies Hirschsprung disease risk. *Nature* 434: 857–863.
46. Shin MK, Levorse JM, Ingram RS, Tilghman SM (1999) The temporal requirement for endothelin receptor-B signalling during neural crest development. *Nature* 402: 496–501.
47. Manly KF, Cudmore RH, Jr., Meer JM (2001) Map Manager QTX, cross-platform software for genetic mapping. *Mammalian Genome* 12: 930–932.